Inorganic Chemistry · 2021 · 35 citations · 52 references
MedicineMedicinal ChemistryOncologyCancer PharmacologyChemotherapyMolecular OncologyCytotoxic ChemotherapyMitotic InhibitorsCancer Cell Proliferation InhibitionCancer Targeting LigandsCell Cycle DynamicsCell Cycle InhibitionOrganometallic Anticancer AgentsReactive Oxygen Species GenerationTumor Targeting LigandsTumor-targeted Ligands
Half-sandwiched structure iridium(III) complexes appear to be an attractive organometallic antitumor agents in recent years. Here, four triphenylamine-modified fluorescent half-sandwich iridium(III) thiosemicarbazone (TSC) antitumor complexes were developed. Because of the “enol” configuration of the TSC ligands, these complexes formed a unique dimeric configuration. Aided by the appropriate fluorescence properties, studies found that complexes could enter tumor cells in an energy-dependent mode, accumulate in lysosomes, and result in the damage of lysosome integrity. Complexes could block the cell cycle, improve the levels of intrastitial reactive oxygen species, and lead to apoptosis, which followed an antitumor mechanism of oxidation. Compared with cisplatin, the antitumor potential in vivo and vitro confirmed that Ir4 could effectively inhibit tumor growth. Meanwhile, Ir4 could avoid detectable side effects in the experiments of safety evaluation. Above all, half-sandwich iridium(III) TSC complexes are expected to be an encouraging candidate for the treatment of malignant tumors.
52
Maria Eugenia Guicciardi, Marcel Leist, Gregory J. Gores · Oncogene · 2004 · 709 citations
Targeted photoredox catalysis in cancer cells
Huaiyi Huang, Samya Banerjee, Kangqiang Qiu et al. · Nature Chemistry · 2019 · 524 citations · Full text
Medicine, Cancer Biology, Oncology +12
Organometallic Half-Sandwich Iridium Anticancer Complexes
Zhe Liu, Abraha Habtemariam, Ana M. Pizarro et al. · Journal of Medicinal Chemistry · 2011 · 353 citations · Full text
Medicine, Oncology, Pharmacology +16